Lactobacillus reuteri DSM 17938 is effective in the treatment of functional abdominal pain in children: Results of the double-blind randomized study

Jadrešin, Oleg; Sila, Sara; Trivić, Ivana; Mišak, Zrinjka; Kolaček, Sanja; Hojsak, Iva

doi:10.1016/j.clnu.2020.04.019

Cited by 20 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pain was less severe in the probiotic treatment group and the children had more days without pain during the study [52,53] Recurrent abdominal pain in children…”

Section: Recurrent Abdominal Pain In Childrenmentioning

confidence: 99%

“…Examples are included that focus on pain associated with gastrointestinal issues (ulcerative colitis and irritable bowel), osteoarthritis, probiotics and headaches, post-surgical pain, neurologic and visceral pain, menopausal status, the risk-benefit role of opioids, the connections between microbiota and microglia activation, and gut microbiota as pertains to pain hypersensitivity vs. tolerance. While a variety of microbiome studies are described within the review articles in Table 1, the most recent preclinical and clinical trials from the past 2-3 years are highlighted in Table 2 [52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71]. Several areas of activity are notable.…”

Section: Painmentioning

confidence: 99%

See 1 more Smart Citation

Microbiome First Approaches in Pain Prevention and Management

Dietert

2021

AJBSR

View full text Add to dashboard Cite

The Microbiome First Initiative aims to facilitate sustainable healthcare by focusing first and foremost on the human holobiont majority, the microbiome. Understanding how the human microbiome affects not only risk of disease but also human perceptions can help individuals thrive and pave the way for a healthy life course. Following a recent review of Microbiome First Medicine the context of health and safety, this present opinion article considers the role of the human microbiome, particularly the gut microbiome, on pain, sensory perceptions, and the prevention and multimodal management of pain. Microbial dysbiosis can be causative of some forms of immune-inflammatory and neurologic pain and the altered human microbiome can lock in the pain while at the same time interfering with analgesic/opioid therapies. Dysbiotic microbiota can make drug treatments less effective and with opioids, the microbes can significantly increase:1. Opioid tolerance 2. The risk of addiction 3. The likelihood of withdrawal failure.For these reasons, it is critical to move beyond simply thinking about the microbiome in dealing with pain to considering the microbiome as central in multimodal pain prevention and management strategies. The microbiome is key in any attempts to change physiology, metabolism, systems biology function, and receptor-based perceptions within the human body.

show abstract

“…Pain was less severe in the probiotic treatment group and the children had more days without pain during the study [52,53] Recurrent abdominal pain in children…”

Section: Recurrent Abdominal Pain In Childrenmentioning

confidence: 99%

Section: Painmentioning

confidence: 99%

Microbiome First Approaches in Pain Prevention and Management

Dietert

2021

AJBSR

View full text Add to dashboard Cite

show abstract

“…In children with functional abdominal pain disorders, such as functional dyspepsia, functional abdominal pain (FAP), and irritable bowel syndrome (IBS), there is minimal evidence supporting the beneficial role of probiotics. The existence of positive effects of probiotics to decrease pain intensity and frequency in FAP is questionable [ 97 , 98 , 99 , 100 , 101 ]. Prebiotics and fibers.…”

Section: Nutritional Aspects Of Pediatric Gastrointestinal Diseasesmentioning

confidence: 99%

Nutritional Aspects of Pediatric Gastrointestinal Diseases

et al. 2021

View full text Add to dashboard Cite

In the last decade, the role of nutritional management in pediatric gastrointestinal diseases has gained increasing popularity. Disease-specific diets have been introduced as conventional treatments by international guidelines. Patients tend to more willingly accept food-based therapies than drugs because of their relatively “harmless” nature. Apart from a diet’s therapeutic role, nutritional support is crucial in maintaining growth and improving clinical outcomes in pediatric patients. Despite the absence of classical “side effects”, however, it should be emphasized that any dietary modification might have negative consequences on children’s growth and development. Hence, expert supervision is always advised, in order to support adequate nutritional requirements. Unfortunately, the media provide an inaccurate perception of the role of diet for gastrointestinal diseases, leading to misconceptions by patients or their caregivers that tends to overestimate the beneficial role of diets and underestimate the potential adverse effects. Moreover, not only patients, but also healthcare professionals, have a number of misconceptions about the nutritional benefits of diet modification on gastrointestinal diseases. The aim of this review is to highlight the role of diet in pediatric gastrointestinal diseases, to detect misconceptions and to give a practical guide for physicians on the basis of current scientific evidence.

show abstract

“…Moreover, L. Reuteri produces antimicrobial molecules and promotes the development and the functionality of regulatory T cells, strengthening the gut barrier, and decreasing the microbial translocation from the intestinal lumen to the tissue, as reported by studies conducted on animal models [ 7 ], on humans [ 8 ] and in vitro [ 9 ]. Literature preclinical studies [ 10 ], using genetic tools such as genome sequencing, molecular tools, and genomic-based approaches (both in mice and then in humans) showed that L. reuteri has multiple beneficial effects on gastrointestinal symptoms, on gut infections, HP eradication, antibiotic-associated diarrhea, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), and colorectal cancer [ 11 , 12 , 13 ]. It can reduce abdominal pain in infantile colic, the functional abdominal discomfort in children, and it can decrease crying due to necrotizing enterocolitis in preterm neonates [ 12 , 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

“…Numerous clinical studies have been conducted to explore the function of L. reuteri in the intestines of healthy individuals, its role in regulating gut microbiota and mucosal homeostasis, in shaping the intestinal host immune system, and in ameliorating intestinal inflammation in pathological conditions, such as acute watery diarrhea [ 8 , 9 , 10 , 16 , 17 , 18 , 19 ] ( Table S1 ). Literature data provides evidence that the use of lactobacilli leads to an improvement of gut functionality and gastrointestinal symptoms, as reported by Guandalini et al [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Lactobacillus Reuteri DSM 17938 (Limosilactobacillus reuteri) in Diarrhea and Constipation: Two Sides of the Same Coin?

et al. 2021

View full text Add to dashboard Cite

Background and Objectives: Lactobacillus reuteri DSM 17938 (L. reuteri) is a probiotic that can colonize different human body sites, including primarily the gastrointestinal tract, but also the urinary tract, the skin, and breast milk. Literature data showed that the administration of L. reuteri can be beneficial to human health. The aim of this review was to summarize current knowledge on the role of L. reuteri in the management of gastrointestinal symptoms, abdominal pain, diarrhea and constipation, both in adults and children, which are frequent reasons for admission to the emergency department (ED), in order to promote the best selection of probiotic type in the treatment of these uncomfortable and common symptoms. Materials and Methods: We searched articles on PubMed® from January 2011 to January 2021. Results: Numerous clinical studies suggested that L. reuteri may be helpful in modulating gut microbiota, eliminating infections, and attenuating the gastrointestinal symptoms of enteric colitis, antibiotic-associated diarrhea (also related to the treatment of Helicobacter pylori (HP) infection), irritable bowel syndrome, inflammatory bowel disease, and chronic constipation. In both children and in adults, L. reuteri shortens the duration of acute infectious diarrhea and improves abdominal pain in patients with colitis or inflammatory bowel disease. It can ameliorate dyspepsia and symptoms of gastritis in patients with HP infection. Moreover, it improves gut motility and chronic constipation. Conclusion: Currently, probiotics are widely used to prevent and treat numerous gastrointestinal disorders. In our opinion, L. reuteri meets all the requirements to be considered a safe, well-tolerated, and efficacious probiotic that is able to contribute to the beneficial effects on gut-human health, preventing and treating many gastrointestinal symptoms, and speeding up the recovery and discharge of patients accessing the emergency department.

show abstract

Lactobacillus reuteri DSM 17938 is effective in the treatment of functional abdominal pain in children: Results of the double-blind randomized study

Cited by 20 publications

References 23 publications

Microbiome First Approaches in Pain Prevention and Management

Microbiome First Approaches in Pain Prevention and Management

Nutritional Aspects of Pediatric Gastrointestinal Diseases

Lactobacillus Reuteri DSM 17938 (Limosilactobacillus reuteri) in Diarrhea and Constipation: Two Sides of the Same Coin?

Contact Info

Product

Resources

About